Claim OwnershipEndocrine Deep Dives
Subscribed: 6Played: 74
Subscribe
© Gurbir Gill, MD
Description
The Endocrine Deep Dive covers advanced topics in endocrinology. Utilizing AI-driven synthetic audio discussions from my own study notes, each episode breaks down complex endocrine concepts.
Comprehensive Legal & Medical Disclaimer: Endocrine Deep Dives and all associated content, materials, and digital assets are produced strictly for informational and educational purposes only. The program is intended solely for healthcare providers, medical fellows, residents, and students as a supplement to their professional training.
No Physician-Patient Relationship: Listening to this podcast, accessing show notes, or interacting with the platform does not establish a physician-patient, pharmacist-patient, or any other formal professional-client relationship between the host and any listener or patient.
Not Medical Advice: The content does not constitute individualized medical advice, clinical diagnosis, or treatment recommendations. Patients and members of the general public must never use this content to guide personal healthcare decisions and must always consult a qualified, licensed physician or healthcare provider for any medical concerns.
Clinical Responsibility: Healthcare professionals listening to this program must exercise their own independent clinical judgment. The host's interpretations, study notes, and opinions reflect personal perspectives on literature and do not set an official standard of care. Clinicians bear sole responsibility for verifying all pharmacological dosing, diagnostic criteria, and treatment protocols against official institutional guidelines, current primary literature, and individual patient presentation.
Limitation of Liability: The host, creators, and associated entities disclaim any and all liability for direct, indirect, incidental, or consequential damages resulting from the use, misuse, application, or interpretation of any information presented in this podcast. Reliance on any data or opinion provided is solely at the listener's own risk.
Comprehensive Legal & Medical Disclaimer: Endocrine Deep Dives and all associated content, materials, and digital assets are produced strictly for informational and educational purposes only. The program is intended solely for healthcare providers, medical fellows, residents, and students as a supplement to their professional training.
No Physician-Patient Relationship: Listening to this podcast, accessing show notes, or interacting with the platform does not establish a physician-patient, pharmacist-patient, or any other formal professional-client relationship between the host and any listener or patient.
Not Medical Advice: The content does not constitute individualized medical advice, clinical diagnosis, or treatment recommendations. Patients and members of the general public must never use this content to guide personal healthcare decisions and must always consult a qualified, licensed physician or healthcare provider for any medical concerns.
Clinical Responsibility: Healthcare professionals listening to this program must exercise their own independent clinical judgment. The host's interpretations, study notes, and opinions reflect personal perspectives on literature and do not set an official standard of care. Clinicians bear sole responsibility for verifying all pharmacological dosing, diagnostic criteria, and treatment protocols against official institutional guidelines, current primary literature, and individual patient presentation.
Limitation of Liability: The host, creators, and associated entities disclaim any and all liability for direct, indirect, incidental, or consequential damages resulting from the use, misuse, application, or interpretation of any information presented in this podcast. Reliance on any data or opinion provided is solely at the listener's own risk.
103 Episodes
Reverse
Familial hypocalciuric hypercalcemia and normohormonal primary hyperparathyroidism present significant diagnostic overlap, both manifesting with hypercalcemia alongside inappropriately non-suppressed or normal intact parathyroid hormone levels. Differentiating these entities hinges on accurate assessment of renal calcium handling. Calculating the 24-hour urinary calcium-to-creatinine clearance ratio remains the standard initial screening tool, where a ratio below 0.01 strongly suggests familial hypocalciuric hypercalcemia, whereas a ratio above 0.02 favors primary hyperparathyroidism.
Cinacalcet is a positive allosteric modulator of the parathyroid calcium-sensing receptor (CaSR) indicated for hypercalcemia in primary hyperparathyroidism (PHPT) when parathyroidectomy is unfeasible. By enhancing receptor sensitivity to ambient calcium, it suppresses parathyroid hormone (PTH) secretion, normalizing serum calcium in up to 76% of patients. Crucially, cinacalcet does not improve bone mineral density or alter urinary calcium excretion. Initiation starts at 30 mg twice daily with food, titrating every 2-4 weeks. Monitoring requires weekly serum calcium during titration, every 2 months during maintenance, and tracking CYP2D6 inhibition and hepatic impairment.
Oncocytic thyroid carcinoma, historically classified as a Hürthle cell variant of follicular carcinoma, represents a distinct clinical entity driven by mitochondrial DNA mutations and widespread chromosomal loss of heterozygosity. Pathologically defined by over 75 percent eosinophilic, mitochondria-dense cells, it exhibits an aggressive phenotype with heightened rates of distant metastasis and structural recurrence. Crucially, metabolic mitochondrial dysfunction leads to loss of sodium-iodide symporter expression, rendering these tumors intrinsically resistant to radioactive iodine therapy despite high fluorodeoxyglucose avidity on PET imaging. Management prioritizes complete surgical resection, with systemic kinase inhibitors indicated for progressive, refractory disease.
Glucocorticoid-induced osteoporosis represents the most prevalent form of secondary bone loss, driven by rapid osteoblast apoptosis, suppressed bone formation, and transiently elevated osteoclast-mediated resorption. Skeletal deterioration occurs rapidly within the first three months of therapy, independent of bone mineral density, necessitating early risk stratification with FRAX and Vertebral Fracture Assessment. Management mandates immediate daily calcium and vitamin D optimization alongside prompt initiation of systemic pharmacotherapy for individuals at high fracture risk. Bone-forming anabolic agents demonstrate superior efficacy in restoring microarchitecture and reducing fracture incidence compared to standard antiresorptives in this low-bone-turnover state.
Comments
Download from Google Play
Download from App Store
United States